Design, synthesis, characterization, and cytotoxicity activity evaluation of mono-chalcones and new pyrazolines derivatives

The development of resistance and side effects of chemotherapeutic drugs are common obstacles in the treatmentof cancer. With the expansion of health problems nowadays, there is a need to continuously develop new drugs thatare more efficient in targeting tumor cells and safe to normal cells. This study designed a series of new chalconesand pyrazoline derivatives based on their binding energy from the molecular docking study. The synthesis involvedClaisen–Schmidt condensation to form two chalcones, 1 and 2, which are then cyclized at room temperature to formeight new pyrazoline derivatives, 3–10. A one-pot reaction of acetophenone, 2-ethoxybenzaldehyde, and hydrazidederivatives (thiosemicarbazide and phenyl hydrazide) under reflux formed two new pyrazoline derivatives, 11 and12, without the isolation of chalcones. All the synthesized chalcones and pyrazolines were characterized using theFourier transform infrared spectroscopy–attenuated total reflectance and nuclear magnetic resonance (1D and 2D).The cytotoxicity activity of the chalcones and new pyrazoline compounds were investigated against breast cancercell lines (MCF-7 and MD-MB-231) and normal breast cell lines (MCF-10A). The results show that only compound7 showed the minimum inhibition against MCF-7 with IC50 6.50µM when exposed to the cell line for 24 hourscompared to the reference Gefitinib anticancer drug

A Review On Pyrazoline Derivatives As Antimicrobial Agent

At present, there is a lot of research about the pyrazoline heterocyclic compound, its ring structure is being changed and new derivatives are being made, many of which have antimicrobial activity over the derivatives. Pyrazoline is the five-member heterocyclic ring which have two N atoms in nearby position and contains two endocyclic double bonds. Noteworthy consideration has been concentrated on pyrazolines and pyrazoline derivative due to their important pharmacological action. Some replaced pyrazolines have been stated near retain particular important pharmacological actions as antimicrobial, antifungal, antineoplastic, antidepressant, insecticidal, anticonvulsant, anti-inflammatory, antibacterial and antitumor properties.

In vitro cytotoxicity and druglikeness of pyrazolines and pyridines bearing benzofuran moiety

A series of pyrazolines and pyridines bearing benzofuran moiety (M1–M10) were synthesized for evaluation of theirin vitro cytotoxicity against MCF-7 and HepG2 cell lines. Furthermore, in silico drug-likeness study was carried out.The result of the cytotoxicity of M1–M10 showed that some compounds displayed cytotoxic activity against MCF-7and HepG2 cells. An assessment of in silico drug-likeness study of M1–M10 illustrates that some compounds showedan agreement to the Lipinski, Ghose, Veber, Egan, and Muegge rules with orally bioavailable.

Antimicrobial evaluation and molecular properties prediction of pyrazolines incorporating benzofuran and pyrazole moieties

A series of chalcones 3–5, 1H-pyrazolines 6–8, N-phenylpyrazolines 9–11, and N-acetylpyrazolines 12–14incorporating benzofuran and pyrazole moieties were synthesized and screened for their in vitro antimicrobial activityagainst some of pathogenic microorganisms. Among the screened compounds, 7 and 13 showed the most promisingantibacterial activity against Escherichia coli (G-). Compound 11 displayed broad spectrum antibacterial activityagainst Bacillus subtilis (G+). Moreover, compounds 10 and 4 were found to be the most potent antifungal agentagainst Candida albicans and Aspergillus niger, respectively. Also, the molecular properties prediction and druglikeness model score (DLS) of all the synthesized compounds were calculated by SwissADME and MolSoft websites,respectively. The two compounds 7 and 13 were found to be maximum DLS of 0.75 and 0.83, respectively.

Synthesis, anticancer activity, and docking study of N-acetyl pyrazolines from veratraldehyde

N-acetyl pyrazoline derivatives A–C containing methoxy and chloro/hydroxyl substituents were synthesized andtested for their cytotoxic activities. The precursor chalcones A–C which were obtained from the condensation reactionbetween veratraldehyde and acetophenone derivatives were reacted with hydrazine hydrate in the presence of glacialacetic acid to give pyrazolines A–C with excellent yield and purity. Characterization of all products was done usingFourier transform infrared (FTIR), nuclear magnetic resonance (NMR) and gas chromatography-mass spectrometers.(GC-MS). Cytotoxicity evaluation of pyrazolines revealed that pyrazoline A has moderate activity against breastcancer cell line MCF7 (IC50 40.47 µg/ml), breast cancer cell line T47D (IC50 26.51 µg/ml), and cervical cancer cell lineHeLa (IC50 31.19 µg/ml). Pyrazoline B is inactive against all tested cancer lines (IC50 > 100 µg/ml). Pyrazoline C hasmoderate activity against MCF7 (IC50 94.02 µg/ml), but inactive against T47D and HeLa. Docking study showed theinteraction between pyrazolines and EGFR receptor via hydrogen bonds and π-cation interactions.

Synthesis, anticancer activity, and docking study of N-acetyl pyrazolines from veratraldehyde

N-acetyl pyrazoline derivatives A–C containing methoxy and chloro/hydroxyl substituents were synthesized andtested for their cytotoxic activities. The precursor chalcones A–C which were obtained from the condensation reactionbetween veratraldehyde and acetophenone derivatives were reacted with hydrazine hydrate in the presence of glacialacetic acid to give pyrazolines A–C with excellent yield and purity. Characterization of all products was done usingFourier transform infrared (FTIR), nuclear magnetic resonance (NMR) and gas chromatography-mass spectrometers.(GC-MS). Cytotoxicity evaluation of pyrazolines revealed that pyrazoline A has moderate activity against breastcancer cell line MCF7 (IC50 40.47 µg/ml), breast cancer cell line T47D (IC50 26.51 µg/ml), and cervical cancer cell lineHeLa (IC50 31.19 µg/ml). Pyrazoline B is inactive against all tested cancer lines (IC50 > 100 µg/ml). Pyrazoline C hasmoderate activity against MCF7 (IC50 94.02 µg/ml), but inactive against T47D and HeLa. Docking study showed theinteraction between pyrazolines and EGFR receptor via hydrogen bonds and π-cation interactions